Provided by Tiger Trade Technology Pte. Ltd.

Marker Therapeutics, Inc.

1.48
-0.1000-6.33%
Post-market: 1.510.0300+2.03%19:43 EST
Volume:65.67K
Turnover:99.81K
Market Cap:24.68M
PE:-1.26
High:1.60
Open:1.55
Low:1.47
Close:1.58
52wk High:4.07
52wk Low:0.8099
Shares:16.67M
Float Shares:14.12M
Volume Ratio:0.38
T/O Rate:0.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1700
EPS(LYR):-1.1950
ROE:-110.67%
ROA:-55.19%
PB:1.34
PE(LYR):-1.24

Loading ...

Company Profile

Company Name:
Marker Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
5
Office Location:
2450 Holcombe Blvd,MS: BCM251,Houston,Texas,United States
Zip Code:
77021
Fax:
- -
Introduction:
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Directors

Name
Position
Juan Vera
President, Chief Executive Officer, Treasurer and Director
David Eansor
Independent Director
Katharine Knobil
Independent Director
Steven Elms
Independent Director
Kathryn Penkus Corzo
Director

Shareholders

Name
Position
Juan Vera
President, Chief Executive Officer, Treasurer and Director
Maria Bernadette Madel
Director, Corporate Operations and External Communications